Toronto, Canada,- Axela Inc. announced today it has entered into a development agreement to integrate Thermal Gradient’s rapid PCR technology into Axela’s Flow-Thru Chip® automated workflow. Thermal Gradient’s sample preparation and amplification technology will initially be added to Axela’s patent pending approach for the capture and quantification of targeted nucleic acids. Currently optimized for formalin […]

Leica Biosystems announced that it has acquired Kreatech Diagnostics, a privately-held provider of DNA fluorescent in-situ hybridization (FISH) probes and target labeling reagents for microarrays. “We are very pleased with the acquisition of Kreatech, its extensive portfolio and development expertise. This will allow Leica Biosystems to better serve our cytogenetics and anatomic pathology customers. It […]

UCART19 is a revolutionary engineered T-cell product that leverages Cellectis’ core technologies in genome engineering. This standardized “off-the-shelf” therapy product is designed with a “chimeric antigen receptor” (CAR) to target and kill the most common types of acute and chronic leukemia and are engineered with Cellectis’ nucleases enabling the use of non-patient derived (allogeneic) T-cells. […]

REDWOOD CITY, Calif.– Illumina, Inc. (NASDAQ: ILMN) today announced that Teva Pharmaceutical Industries Ltd. signed an exclusive agreement with Verinata Health, an Illumina company, for the commercialization of the verifi® non-invasive prenatal test1 in Israel. The MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi® prenatal test to customers […]